Mission & History

We are a company focused on developing oral therapies that halt abnormal protein aggregation to improve the lives of patients suffering from some of the most common and debilitating chronic neurologic diseases.


We have one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients. Asceneuron has two small molecule O-GlcNAcase inhibitors (ASN51 and ASN90) that leverage a central protein modification system to slow protein aggregation. Both ASN51 and ASN90 have completed 3 Phase 1 studies, demonstrating high O-GlcNAcase inhibition in the brain.

Who we are

We are a team of scientists and drug developers supported by a strong syndicate of venture investors and grants from world-renowned patient-focused foundations.


Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and M Ventures.

Our executive management team combines research and development excellence with business and fundraising experience to bring end-to-end innovation to the R&D process. ASN90 and ASN51 have been supported by grants and research awards from Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF), and The Michael J Fox Foundation (MJFF).

Asceneuron operates in a state-of-the-art facility at the EPFL Innovation Park in Switzerland. Our clinical trials are supported by a clinical team located in the United States.

  • $

    Management Team

  • $

    Board of Directors

  • $

    Scientific Advisory Board